Colak Tahsin, Ipek Turgut, Kanik Arzu, Ogetman Zekai, Aydin Suha
Department of General Surgery, Medical Faculty of Mersin University, 33079 Mersin/ICEL/Turkey.
J Am Coll Surg. 2003 Apr;196(4):525-30. doi: 10.1016/S1072-7515(02)01893-8.
The aim of the study was to investigate the effects of topical nonsteroidal antiinflammatory drugs (NSAIDs) on mastalgia.
A prospective, randomized, blinded, placebo-controlled study was performed to evaluate the effects of topical NSAIDs on cyclic and noncyclic mastalgia. A total of 108 patients, 60 with cyclic (group I) and 48 with noncyclic (group II) breast pain were enrolled. Patients within each group were randomly assigned to receive either topical NSAIDs or placebo three times daily for at least 6 months. Severity of pain was measured before and after 6 months of treatment.
The pain score decreased significantly when the mean initial breast pain score was compared with the sixth-month breast pain score of the treatment or the placebo group of cyclic (p = 0.0001 and p = 0.0001, respectively) or noncyclic mastalgia (p = 0.0001 and p = 0.0001, respectively). Significant differences were found when the mean within-person change in pain values in each treatment group were compared with the change in the respective placebo group for either cyclic or noncyclic mastalgia (p = 0.0001 and p = 0.0001, respectively). Changes in pain within treatment groups or placebo groups for cyclic versus noncyclic mastalgia were not found to be statistically different (p = 0.53 and p = 0.96, respectively). No side effect was seen in any group.
Topical application of NSAIDs was effective in both cyclic and noncyclic mastalgia with minimal side effects.
本研究旨在调查外用非甾体抗炎药(NSAIDs)对乳腺疼痛的影响。
进行了一项前瞻性、随机、双盲、安慰剂对照研究,以评估外用NSAIDs对周期性和非周期性乳腺疼痛的影响。共纳入108例患者,其中60例为周期性乳腺疼痛患者(I组),48例为非周期性乳腺疼痛患者(II组)。每组患者随机分配,每天接受3次外用NSAIDs或安慰剂治疗,至少持续6个月。在治疗6个月前后测量疼痛严重程度。
将治疗组或安慰剂组的周期性(分别为p = 0.0001和p = 0.0001)或非周期性乳腺疼痛(分别为p = 0.0001和p = 0.0001)患者的初始乳腺疼痛平均评分与第6个月的乳腺疼痛评分进行比较时,疼痛评分显著降低。将每个治疗组疼痛值的平均个体内变化与相应安慰剂组的周期性或非周期性乳腺疼痛变化进行比较时,发现存在显著差异(分别为p = 并0.0001和p = 0.0001)。未发现周期性与非周期性乳腺疼痛的治疗组或安慰剂组内疼痛变化有统计学差异(分别为p = 0.53和p = 0.96)。任何组均未观察到副作用。
外用NSAIDs对周期性和非周期性乳腺疼痛均有效,且副作用最小。